PLEKHG5 is stabilized by HDAC2-related deacetylation and confers sorafenib resistance in hepatocellular carcinoma

PLEKHG5 is stabilized by HDAC2-related deacetylation and confers sorafenib resistance in hepatocellular carcinoma

Abstract Sorafenib is the first FDA-approved first-line targeted drug for advanced HCC. However, resistance to sorafenib is frequently observed in clinical practice, and the molecular mechanism remains largely unknown. Here, we found that PLEKHG5 (pleckstrin homology and RhoGEF domain containing G5)...

Full description

Bibliographic Details
Main Authors: Yu Sha, Mingang Pan, Yunmeng Chen, Liangjun Qiao, Hengyu Zhou, Dina Liu, Wenlu Zhang, Kai Wang, Luyi Huang, Ni Tang, Jianguo Qiu, Ailong Huang, Jie Xia
Format: Article
Language:English
Published: Nature Publishing Group 2023-05-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-023-01469-z

Internet

https://doi.org/10.1038/s41420-023-01469-z

Similar Items